Entry Point Capital, LLC Bio N Tech Se Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding BNTX
# of Institutions
323Shares Held
38.9MCall Options Held
845KPut Options Held
1.28M-
Baillie Gifford & CO8.31MShares$896 Million0.75% of portfolio
-
Primecap Management CO Pasadena, CA4.79MShares$517 Million0.28% of portfolio
-
Flossbach Von Storch Ag Cologne, 2M4.38MShares$472 Million1.49% of portfolio
-
Harding Loevner LP Bridgewater, NJ2.93MShares$316 Million1.34% of portfolio
-
Black Rock Inc. New York, NY1.9MShares$204 Million0.0% of portfolio
About BioNTech SE
- Ticker BNTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 242,684,992
- Market Cap $26.2B
- Description
- BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...